Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.02 +1.23%

+$0.04 today

Market cap
$220.03M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 5.46M

Average 3.33M

CABA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Cabaletta Bio, Inc.NASDAQ: CABA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows in line with its trailing trend

Q1 FY2026 stock-based compensation of $5.26M rose 1.8% year over year, ahead of the +1.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 23.4% from the prior quarter. Over 3 fiscal years it compounded at +44.8% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.8% holds above the trailing-twelve-month pace of +1.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.26M+23.4% QoQ
Last fiscal yearDec 2025
$20.94M+7.6% YoY
LTMMar 2026
$21.03M+1.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.8%——
1 year+7.6%——
3-year CAGR+44.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
20.94M USD
Year-over-year change
+7.6%
4-year CAGR
+37.8%

Stock-Based Compensation vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.0% is the 5th highest of 11, against a peer median of -20.1%.
  • Over three fiscal years its annual growth of +44.8% compares with a peer median of +4.3%.
CABA Competitors
Stock-Based Compensation for CABA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.98B USD+32410.1%+56.9%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M USD+19.3%—115500.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M USD-35.1%-23.4%—
CABACabaletta Bio, Inc.LTM Mar 2026$21.03M USD+1.0%+44.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M USD-62.1%-23.7%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$11.19M USD-19.1%+89.6%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$11.09M USD+34.6%+121.4%—
HUMAHumacyte, Inc.LTM Mar 2026$10.44M USD+45.6%+16.4%517.7%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M USD-45.7%-30.1%23.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
IMMPImmutep LimitedFY2025A$1.16M AUD-35.2%-7.8%23.1%
Peer median (excluding CABA) —-20.1%+4.3%23.6%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
Deferred Income Tax00000
Stock-Based Compensation5.8M6.9M11.34M19.47M20.94M
Change in Working Capital5.58M(4.3M)101K1.61M(379K)
Accounts Receivables00000
Inventory00000
Accounts Payables975K(28K)1.68M1.01M1.55M
Other Working Capital4.61M(4.27M)(1.57M)600K(1.93M)
Other Non-Cash Items62K2.82M1.26M4.86M14.57M
Operating Cash Flow(34.11M)(46.38M)(53.55M)(88.22M)(131.08M)
Capital Expenditures(1.17M)(2.45M)(687K)(2.21M)(1.23M)
Acquisitions (Net)024.76K000
Purchases of Investments0(49.76M)(84.26M)0(99.04M)
Sales of Investments7.17M25M62.5M49.5M50M
Other Investing Activities0(24.76K)000
Investing Cash Flow6M(27.22M)(22.45M)47.29M(50.27M)
Debt Repayment000(897K)(6.26M)
Common Stock Issued48.25M32.86M185.2M10.88M106.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities650K127K2.43M1.7M0
Financing Cash Flow48.9M32.98M187.63M11.68M100.35M
Effect of Forex Changes000(20K)19K
Net Change in Cash20.79M(40.62M)111.63M(29.28M)(80.98M)
Free Cash Flow(35.28M)(48.83M)(54.24M)(90.43M)(132.31M)

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.